Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials

Annals of Oncology

Volumn 29, Issue 12, 2018, Pages 2396-2398

  Sen, S ^a   Carmagnani Pestana, R ^a   Hess, K ^a   Viola, G M ^a   Subbiah, V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM; IMMUNOMODULATING AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; ANTIINFECTIVE AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LETTER; MELANOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RENAL CELL CARCINOMA; SARCOMA; TREATMENT OUTCOME; CANCER STAGING; DRUG EFFECT; IMMUNOLOGY; INTESTINE FLORA; MORTALITY; NEOPLASM; PATHOLOGY; TIME FACTOR;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CLINICAL TRIALS, PHASE I AS TOPIC; CTLA-4 ANTIGEN; GASTROINTESTINAL MICROBIOME; HUMANS; NEOPLASM STAGING; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROGRESSION-FREE SURVIVAL; TIME FACTORS;

EID: 85059290786     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy453     Document Type: Letter

References (6)

1. Derosa L, Hellmann MD, Spaziano M et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 2018; 29(6): 1437-1444.
2. Gilbert JA, Blaser MJ, Caporaso JG et al. Current understanding of the human microbiome. Nat Med 2018; 24(4): 392.
3. Vétizou M, Pitt JM, Daillère R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350(6264): 1079.
4. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest 2014; 124(10): 4212-4218.
5. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018; 359(6371): 91.
6. Sen S, Hess K, Hong DS et al. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 2018; 118(6): 763.